BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
1W: +2.4%
1M: +5.6%
3M: +22.8%
YTD: +69.8%
1Y: +133.1%
$26.88
-0.93 (-3.34%)
Weekly Expected Move ±7.0%
$23
$25
$27
$29
$31
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$4.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.5B
52W Range9.57-30.99
Volume457,093
Avg Volume672,014
Beta-0.81
Dividend—
Analyst Ratings
Company Info
CEOClaire Mazumdar Clemon
Employees103
SectorHealthcare
IndustryBiotechnology
IPO Date2024-09-13
Websitebicara.com
116 Huntington Avenue
Boston, MA 02116
US
Boston, MA 02116
US
617-468-4219
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Latest News
10 small-cap U.S. healthcare stocks with the strongest momentum grades
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
Bicara (BCAX) Q4 2025 Earnings Transcript
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mazumdar Claire | S-Sale | 9,972 | $28.42 | 2026-07-10 |
| Mazumdar Claire | S-Sale | 28 | $29.68 | 2026-07-10 |
| Cohlhepp Ryan | S-Sale | 536 | $29.00 | 2026-07-09 |
| Cohlhepp Ryan | S-Sale | 22,833 | $28.76 | 2026-07-08 |
| Cohlhepp Ryan | S-Sale | 4,306 | $29.80 | 2026-07-08 |